FDA approves novel antibiotic EMBLAVEO

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections. The drug – a combination of beta-lactam antibiotic aztreonam with beta ...